+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID04628767

Evaluating Durvalumab Combined with Chemotherapy Before Surgery in Patients with High-Grade Upper Urinary Tract Urothelial Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-10-30

131

Participants Needed

258

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of adding the immunotherapy drug durvalumab to chemotherapy before surgery in patients with high-grade upper urinary tract urothelial cancer. This phase IIIII trial compares durvalumab combined with chemotherapy to chemotherapy alone to see if the combination better prevents cancer progression or recurrence. The study focuses on patients eligible or ineligible for cisplatin chemotherapy and aims to improve outcomes such as event-free survival and pathologic response at surgery. Participants receive different treatments based on their eligibility for cisplatin. Those eligible are randomized to receive durvalumab with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin aMVAC or chemotherapy alone in four cycles every 14 days. Patients ineligible for cisplatin receive durvalumab plus gemcitabine every 21 days for up to four cycles. After systemic treatment, patients undergo surgery within 21 to 60 days if no metastatic or unresectable disease is present. Throughout the trial, tissue biopsies, blood samples, CT scans, and MRIs are performed. During the study, participants are closely monitored with imaging and lab tests. Follow-up visits occur within 30 days after treatment and then every 3 to 6 months for up to 5 years. Researchers measure event-free survival, pathologic complete response, overall survival, disease-free survival, cancer-specific survival, renal function after treatment and surgery, and safety outcomes. This long-term monitoring helps evaluate the impact of adding durvalumab to chemotherapy before surgery.

CONDITIONS

Brief Title

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here